Our study provides compelling evidence that SSTR2 is not merely an overexpressed marker in HCC but may participate in a broader oncogenic signaling network that contributes to tumor progression, invasion, and poor clinical outcomes. This evidence concerns the gene SSTR2 and hepatocellular carcinoma.